Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

(MENAFN- GlobeNewsWire - Nasdaq) RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to one new non-executive employee.

The awards were granted under Mineralys' 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of each award's vesting commencement date, February 23, 2026, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The restricted stock units will vest over a four-year period, with 25% of the shares vesting on each of the four anniversaries of each award's vesting commencement date, February 23, 2026. The awards were granted as an inducement material to the new non-executive employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit . Follow Mineralys on LinkedIn, Twitter and Bluesky.

Contact:

Investor Relations

...

MENAFN26022026004107003653ID1110796124